C
Cambium Medical Technologies
Focuses on the development and commercialization of regenerative therapies derived from novel processed human platelets
About Cambium Medical Technologies
Cambium Medical Technologies specializes in regenerative therapies using novel processed human platelets. The company primarily serves the healthcare sector, focusing on conditions like dry eye syndrome. Operating within the biopharmaceutical market, Cambium employs a business model centered on research and development, clinical trials, and partnerships with strategic manufacturers. Revenue is generated through product sales, licensing agreements, and potential third-party reimbursements. Cambium's innovative approach has garnered attention at various investor summits and medical conferences, highlighting its potential for significant impact in regenerative medicine.
Source: Dealroom company dataNews
Open roles
Cambium Medical Technologies in the Atlanta ecosystem
The Cambium Medical Technologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Georgia Research Alliance
National Institutes of Health
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cambium Medical Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cambium Medical Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
